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Treating Opioid Dependence With Injectable
Extended-Release Naltrexone (XR-NTX)
Who Will Respond?
Edward V. Nunes, MD, Evgeny Krupitsky, MD, PhD, Walter Ling, MD, Jacqueline Zummo, MPH, MBA,
Asli Memisoglu, ScD, Bernard L. Silverman, MD, and David R. Gastfriend, MD
Objectives: Once-monthly intramuscular extended-release naltrex-
one (XR-NTX) has demonstrated efficacy for the prevention of re-
lapse in opioid dependence, providing an alternative to agonist or
partial agonist maintenance (ie, methadone and buprenorphine). The
question remains, for whom is this unique treatment most efficacious
and can patient-treatment matching factors be identified?
Methods: A moderator analysis was conducted on a previously re-
ported 24-week, placebo-controlled, multisite, randomized controlled
trial of XR-NTX (n = 126) versus placebo (n = 124) among recently
detoxified opioid-dependent adults in Russia, which showed XR-
NTX superior to placebo in proportion of opioid abstinent weeks.
The moderator analysis examined a dichotomous indicator of good
clinical response—achieving at least 90% of weeks abstinent over the
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24-week trial. A series of logistic regression models were fit for this
outcome as functions of treatment (XR-NTX vs placebo), each base-
line moderator variable, and their interactions. The 25 baseline vari-
ables included demographics, clinical severity (Addiction Severity
Index, SF-36, and Clinical Global Impression-Severity), functioning
(EQ-5D), craving, and HIV serostatus (HIV+).
Results: More XR-NTX patients achieved 90% abstinence (64/126,
51%) versus placebo (39/124, 31%; P = 0.002). There were no sig-
nificant interactions between baseline variables and treatment. There
was a significant main effect of Clinical Global Impression-Severity
score (P = 0.02), such that higher severity score was associated with
a lower rate of Good Clinical Response.
Conclusions: The absence of significant baseline by treatment inter-
actions indicates that no patient-treatment matching variables could
be identified. This suggests that XR-NTX was effective in promoting
abstinence from opioids across a range of demographic and severity
characteristics.
Key Words: abstinence, clinical severity, extended-release naltrex-
one, opioid dependence, predictors
(J Addict Med 2015;9: 238–243)
O pioid dependence is a serious public health problemthroughout the world, responsible for substantial
morbidity, mortality (Stotts et al., 2009), and social costs
(Birnbaum et al., 2011). Maintenance treatment with the opi-
oid agonist methadone, and the partial agonist buprenorphine,
has proved to be highly effective across multiple clinical trials
(Mattick et al., 2003; Mattick et al., 2009) at reducing opioid
use, improving social functioning, reducing criminal involve-
ment, and infectious disease transmission in opioid-dependent
patients. However, not all patients treated with methadone
or buprenorphine respond well, and many opioid-dependent
individuals avoid these treatments due to such factors as
stigma, poor response in a prior treatment episode, fear of
physical withdrawal upon treatment cessation, or patient
preferences. The result is that, even in geographic regions
where methadone and buprenorphine are readily available, a
large proportion of opioid-dependent patients are not engaged
in treatment or provided pharmacotherapy. Furthermore, there
are regions of the United States, and countries around the
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world, where methadone and buprenorphine are not legally
available or readily accessible (International Harm Reduction
Association, 2010; Krupitsky et al., 2010).
Naltrexone is a high-affinity opioid receptor antagonist,
which produces potent blockade of the effects of opioids. How-
ever, until recently naltrexone was available only in daily pill
form, and its effectiveness in practical terms was severely
limited by poor adherence. It is easy for patients to stop the
medicine (there are no withdrawal effects), and once blockade
wears off, relapse becomes likely. The last decade has seen
the development of several versions of long-acting injectable
(Comer et al., 2006; Krupitsky et al., 2011) and implantable
(Reece, 2007; Lobmaier et al., 2008; Mattick et al., 2009;
Krupitsky and Blokhina, 2010) formulations of naltrexone,
which has demonstrated efficacy in controlled clinical trials.
Long-acting formulations circumvent problems with daily pill
adherence and have produced treatment retention rates in clin-
ical trials (Substance Abuse and Mental Health Services Ad-
ministration, 2012) and posttreatment safety records (Hulse
et al., 2009) that resemble those observed for buprenorphine
and methadone.
Once-monthly intramuscular extended-release naltrex-
one (XR-NTX, Vivitrol; Alkermes, Inc, Waltham, MA) has
thus emerged as a viable alternative to methadone and
buprenorphine (Gastfriend, 2011), broadening the treatment
options for opioid-dependent patients and for communities
and treatment systems seeking to address this pandemic. This
naturally raises the question—what types of patients are most
likely to respond well to XR-NTX? The failure of oral nal-
trexone in placebo-controlled trials (Kirchmayer et al., 2003;
Johansson et al., 2006; Minozzi et al., 2011) and the hypoth-
esis that opioid-dependent patients suffer from an underactive
endogenous opioid system thatmight beworsened by an antag-
onist (Goldstein, 1991) have raised concerns that naltrexone
may be a niche treatment useful for only a narrow segment
of the opioid-dependent population, for example, health pro-
fessionals in monitored recovery programs. Previous research
suggested that oral naltrexone may be less successful among
opioid-dependent patients who have a history of methadone
use (Sullivan et al., 2006), greater physiological dependence
on opioids (higher daily opioid intake) (Sullivan et al., 2007;
Carpenter et al., 2009), depression (Sullivan et al., 2006), and
who “test the blockade” using opiates early in a course of
naltrexone treatment (Sullivan et al., 2007; Carpenter et al.,
2009). We, therefore, conducted a secondary analysis of a
previously reported placebo-controlled randomized controlled
trial of XR-NTX (Krupitsky et al., 2011), examining a range
of baseline demographic variables and other clinical charac-
teristics measured at baseline, some of which are indicators of
severity of illness to explore the extent to which any of these
variables predict better or worse outcome on XR-NTX com-
pared with placebo. Although this was an exploratory analysis,
the guiding hypothesis, based on the prior findings with oral
naltrexone (Sullivan et al., 2007; Carpenter et al., 2009), was
that XR-NTX would be relatively more efficacious among pa-
tientswithmilder severity of opioid dependence and associated
problems including medical consequences, HIV, hepatitis C,
and chronicity.
METHODS
Participants
The study, described in detail elsewhere (Krupitsky
et al., 2011), was conducted at 13 sites in Russia and recruited
adults 18 years old and older who met criteria for opioid (pri-
marily heroin) dependence disorder, completed inpatient opi-
oid detoxification (≤30 days), and were off opioids for 7 days
or more. Patients were volunteers (ie, not under justice sys-
tem coercion) who had a significant other who would super-
vise the subject’s study compliance. Women of childbearing
potential agreed to use contraception during the study. Exclu-
sions included pregnancy or breastfeeding; significant medical
conditions; positive naloxone challenge (vital sign elevations
or opioid withdrawal symptoms); hepatic failure, past/present
history of an AIDS-indicator disease, active hepatitis, and/or
liver enzyme elevations 3X or more upper limit of normal;
known intolerance and/or hypersensitivity to XR-NTX or its
components; active psychosis, bipolar disorder, major depres-
sive disorder with suicidal ideation, or current substance de-
pendence other than opioids or heroin; positive urine test for
cocaine/amphetamines/benzodiazepines; alcohol use disorder
or dependence; or naltrexone use within the last 6 months. All
study sites obtained institutional review board approval, and
participants gave written informed consent in accordance with
the Helsinki Accords.
Procedures
Patients were randomized to receive either XR-NTX 380
mg or placebo in a 1:1 ratio, which was administered within
1 week after detoxification and every 4 weeks through the 24-
week study period. Sites also provided 12 biweekly sessions
of manualized Individual Drug Counseling from psychologists
or psychiatrists (Mercer and Woody, 1999).
Double-blinded treatment was maintained among pa-
tients, investigators, staff, and the sponsor by using amber
vials and syringes. Different personnel conducted the coun-
seling than the data collection. Treatment was offered to pa-
tients at no expense and upon completion, patients were of-
fered 12 months of open-label XR-NTX treatment. Patients
were not permitted to be prescribed naltrexone, opioids, an-
tipsychotics, anticonvulsants, antidepressants, and anxiolytics;
however, they could receive stable dosing of anticonvulsants
for seizure disorder treatment and short-acting PRN insom-
nia medications but not to treat symptoms of withdrawal. An
emergency treatment plan for pain management included the
use of nonsteroidal anti-inflammatory drugs, regional anal-
gesia, conscious sedation with a benzodiazepine, or general
anesthesia.
Assessments
Abstinence assessments were conducted weekly over
24 weeks. Confirmed abstinence was defined as a negative
urine drug test for morphine and methadone and no self-
reported opioid use on the timeline follow-back survey. Opi-
oid urine drug testing (immunochromatography-based 1-step
in vitro tests) was performed for morphine and methadone
concentrations 300 ng/mL or more. The timeline follow-back
Copyright © 2015 American Society of Addiction Medicine. Unauthorized reproduction of this article is prohibited.
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survey uses calendars and daily recall of substance use on spe-
cific days to record quantity or frequency of opioid use (Sobell
and Sobell, 1992). Omission of either of these criteria resulted
in failure to confirm abstinence for the week.
Patient-reported outcome questionnaires were adminis-
tered by the study investigators at baseline and at week 24.
Assessments included the:
 Addiction Severity Index interview that evaluates 7 variables
(medical status, employment and support, drug use, alcohol
use, legal status, family/social status, and psychiatric sta-
tus) with scores normalized from 0 to 1 and higher scores
indicating greater problem severity (McLellan et al., 1992).
 Medical Outcomes Study SF-36v2 (SF-36) Health Sur-
vey questionnaire mental health summary score (emotional
well-being, role limitations due to emotional problems, so-
cial functioning, and vitality) and physical health summary
scores (physical functioning, role limitations due to physi-
cal health problems, pain, general health perceptions) with
scores ranging from 1 to 100 and higher scores indicating
better health (Ware et al., 2000).
 Revised Clinical Global Impression-Severity (CGI-S) scale
is a validated 7-point rating of the patient’s illness rang-
ing from “1” (normal, not at all) to “7” (extremely ill) as
determined by the investigator (Guy, 1976).
 EuroQol Group Health Outcome Measure (EQ-5D) is a
quantitative measure of general health encompassing 5
levels—no problems, slight problems, moderate problems,
severe problems, and extreme problems with scores ranging
from statesworse than dead (<0) to 1 (full health), anchoring
dead at 0 (EuroQol Group, 1990).
 Craving was assessed each week using a self-report Visual
Analogue Scale (VAS) of “need for opioids” (scale: 0-100,
ie, “not at all” to “very much so”) (Krupitsky et al., 2004).
 HIV was assessed at baseline and liver enzymes were as-
sessed at baseline and 24 weeks.
Data Analysis
The principal outcome was a dichotomous response
measure, namely whether or not a patient achieved at least
90% abstinent weeks during the 24-week trial. This is an indi-
cator of good clinical response because it reflects patients who
were both retained in treatment (because patients had to be
present to give a urine) and predominantly abstinent across the
24-week trial. To explore baseline variables as predictors of
outcome and moderators of the effect of medication treatment
(XR-NTX vs placebo), a series of logistic regression models
were fit for each moderator, modeling the dichotomous re-
sponse variable as a function of treatment, the various baseline
variables (ie, main effect term), and the baseline-by-treatment
interaction. Patients meeting the criterion of good clinical re-
sponse were disaggregated by treatment condition and exam-
ined by CGI-S dichotomized into lower severity (scores 1 to
4: normal, borderline, mildly, and moderately ill) and higher
severity (scores: 5 through 7: markedly, severely, and among
the most ill) and HIV serostatus on an exploratory basis. All
analyses are based on intent-to-treat, that is, including all ran-
domized patients who received at least 1 dose of study drug.
Alpha level for predictors or interactions was P < 0.05, with
no correction for multiple comparisons in this exploratory
analysis.
RESULTS
Characteristics of Patients at Baseline
Table 1 displays the baseline characteristics of the sam-
ple stratified by responder status, which was predominantly
male, white, and relatively young (with a mean age of 29.6
years). They had an average of 10 years duration of opioid de-
pendence. Of this sample, 90% or more were sero-positive for
hepatitis C, and 40% or more were HIV+. At baseline, more
than 78% of patients in both clinical outcome groups reported
injection of heroin in the preceding 30 days, with 10% to 25%
using illicit methadone, or prescription narcotics. In addition
to these indicators of baseline severity, the Addiction Sever-
ity Index Drug Use Composite Score for the overall sample
at baseline was 0.242, SF-36 Mental Component Summary
Score was 35.2 (1.5 standard deviations below Russian and
US population norms), and CGI-S ratings found 79% to be
moderately to severely ill. After a mean of 18 days of inpatient
hospital detoxification, craving was still measurable at 20 on
a scale of 0 to 100. As previously published, the primary out-
come analysis showed that, compared with placebo, XR-NTX
increased the proportion of weeks abstinent from opioids and
reduced craving for opioids (Krupitsky et al., 2011).
Overall Treatment Response
The criterion for good clinical response (≥90% urine-
confirmed abstinent weeks over the 24 weeks of the trial) was
achieved by 51.6% (65/126) of patients on XR-NTX, com-
pared with 31.5% (39/124) on placebo (χ2 (1 df); P ≤ 0.002),
supporting the efficacy of XR-NTX in the sample as a whole,
consistent with the previously published findings (Krupitsky
et al., 2011).
Patient Characteristics as Moderators of
Treatment Response
A series of logistic regression models were fit, 1 for each
baseline moderator variable, modeling good clinical response
as a function of treatment (XR-NTX vs placebo), the baseline
moderator variable, and moderator by treatment interaction.
None of the main effects baseline variables was significant,
with the exception of CGI-S, where there was a main effect
(P = 0.02) in the direction of greater severity being associ-
ated with a lower rate of Good Clinical Response. None of the
moderator by treatment interactions was significant (all were
P > 0.05). To explore whether trends in the data fell in the
predicted direction (variables indicative of higher severity as-
sociated with less effectiveness of XR-NTX), we examined de-
scriptively the relationships between baseline variables, treat-
ment, and good clinical response for baseline variables with
interaction terms with P < 0.15. The treatment by CGI-S in-
teraction missed significance (P = 0.09). Figure 1 shows the
proportion of patients with good clinical response, disaggre-
gated by lower (CGI-S score 1-4) versus higher (CGI-S score
5-7) severity and by treatment (XR-NTX vs placebo). As can
be seen in the figure, the main effect seems to be driven by the
placebo group response, in which patients with worse baseline
Copyright © 2015 American Society of Addiction Medicine. Unauthorized reproduction of this article is prohibited.
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TABLE 1. Baseline Demographics by Clinical Response Classification
Clinical Response Classification
≥90% Urine-Confirmed <90% Urine-Confirmed
Abstinent Weeks (N = 103) Abstinent Weeks (N = 147)
Variables
Mean ±SD/
Number (%) Median Range
Mean ±SD/
Number (%) Median Range
Demographics
Age (y) 29.2 ± 4.4 29 21-52 29.8 ± 4.1 30 21-45
Sex
Male 95 (92.2%) 125 (85.0%)
Female 8 (7.8%) 22 (15.0%)
Marital status (married) 23 (22.3%) 32 (21.8%)
Living arrangement (alone vs with family) 4 (3.9%) 6 (4.1%)
Addiction severity
Addiction Severity Index (ASI)
Medical 0.296 ± 0.264 0.278 0.00-0.92 0.267 ± 0.245 0.250 0.00-0.89
Employment 0.709 ± 0.301 0.750 0.04-1.00 0.756 ± 0.254 0.750 0.06-1.00
Alcohol use 0.099 ± 0.111 0.083 0.00-0.63 0.115 ± 0.135 0.084 0.00-0.87
Drug use 0.245 ± 0.074 0.259 0.05-0.40 0.24 ± 0.077 0.254 0.02-0.43
Legal status 0.085 ± 0.107 0.033 0.00-0.45 0.082 ± 0.11 0.000 0.00-0.45
Family/social 0.301 ± 0.215 0.253 0.00-0.89 0.312 ± 0.197 0.322 0.00-0.90
Psychiatric 0.15 ± 0.181 0.045 0.00-0.80 0.119 ± 0.153 0.045 0.00-0.64
Clinical Global Impression-Severity (CGI-S)
Lower severity (score: 1 to 4) 82 (79.6%) 100 (68.0%)
Higher severity (score: 5-7) 20 (19.4%) 43 (29.3%)
Missing 1 (1.0%) 4 (2.7%)
Opioid dependence duration (y) 8.9 ± 3.9 10 1-23 10 ± 4.4 10 1-26
Age at onset of opioid dependence 20.3 ± 4.1 19 12-37 19.8 ± 4.3 19 12-33
Methadone use in 30 d prebaseline 10 (9.8%) 19 12.9%
Days inpatient detox before study entry 16.7 ± 7.6 15 6-56 18.4 ± 7.7 17 5-67
Craving—at baseline 18.1 ± 20.3 10 0-85 21.3 ± 25.5 10 0-98
Mental and physical health
SF-36
Physical component 50.6 ± 6.2 50.7 34.1-62.9 50.5 ± 5.4 50.6 35.8-62.5
Mental component 35.7 ± 10.3 36.8 12.5-58.2 34.8 ± 10.7 35.3 5.2-59.7
EQ-5D
Self-care
No problems with self-care 96 (93.2%) 136 (93.2%)
Mobility
No problems walking about 85 (82.5%) 120 (82.2%)
Usual activities
No problems performing my usual activities 62 (60.2%) 90 (61.6%)
Pain/discomfort
No pain or discomfort 56 (54.4%) 86 (58.9%)
Anxiety/depression
Moderately anxious/depressed 59 (57.3%) 84 (57.5%)
HIV sero-positive 40 (38.8%) 66 (44.9%)
severity were less likely to have a good outcome with counsel-
ing plus placebo. Extended-release naltrexone seems to show
a similar benefit in both the lower and higher severity groups,
which is in the opposite direction fromwhat was hypothesized.
Four other variables (HIV serostatus, SF-36 Mental Compo-
nent, EQ-5D Health subscale, and baseline craving) yielded
interaction terms that approached significance (0.05 < P <
0.15). Examination of the data similarly showed the nonsignif-
icant trends in the direction of greater difference between XR-
NTX and placebo among HIV positive patients (Fig. 1) and
those with greater severity on the other variables (data not
shown).
DISCUSSION
The previously reported pivotal trial of XR-NTX in pre-
venting relapse among opioid-dependent patients (Krupitsky
et al., 2011) provided an opportunity to examine the effi-
cacy of this once-monthly μ-opioid antagonist formulation
in important populations (eg, HIV+ patients) and to exam-
ine whether other patient characteristics may moderate the
therapeutic effect of XR-NTX for opioid dependence. The
traditional consensus on naltrexone as a treatment for opioid
dependence, stemming from years of experience with oral nal-
trexone, has been that oral naltrexone is a niche treatment, ef-
fective mainly for a narrow range of good prognosis patients,
such as professionals with high motivation and good social
supports or patients supported with intensive behavioral treat-
ments reinforcing adherence (Preston et al., 1999;Carroll et al.,
2001; Nunes et al., 2006). The monthly injection formulation,
however, was called for to address the poor adherence that
has plagued oral naltrexone, which requires adherence with
daily pill taking (Willette, 1976). The analysis described here
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FIGURE 1. Good clinical response (1) stratified by baseline
Clinical Global Impression-Severity of illness and HIV serosta-
tus. Top panel: Clinical Global Impression-Severity (CGI-S) (2)
is dichotomized into lower severity (scores 1-4: normal, bor-
derline, mildly, and moderately ill) and higher severity (scores:
5 through 7: markedly, severely, and among the most ill).
Bottom panel: HIV serostatus (positive vs negative). (1) Good
Clinical Response is defined as 90% or more urine-confirmed
abstinent weeks over the 24 weeks of the trial. (2) The main
effect of baseline CGI-S is significant (P = 0.02); the baseline
CGI-S by treatment interaction is not significant (P = 0.09). (3)
Neither themain effect of baseline HIV serostatus (P= 0.06) nor
the HIV serostatus by treatment interaction (P = 0.07) is signifi-
cant. Values from 250 opioid-dependent patients who entered
a 24-week randomized, placebo-controlled trial of extended-
release naltrexone (XR-NTX) versus placebo.
therefore examined XR-NTX across 25 demographic and clin-
ical severity variables.
There were no significant interactions between treatment
assignment and any of the baseline variables. Thus, while our
guiding hypothesis was that XR-NTX would be more effi-
cacious for patients with lower severity of illness, there was
no evidence of such patient-treatment matching effects in the
present data. It is possible that there are moderator variables
exerting smaller effects, which were not detected with the
present sample size.
We did examine descriptively the observed proportions
of patients achieving good clinical response for baseline vari-
ables for which the baseline by treatment interaction terms
approached significance (0.05 < P < 0.15), which included
CGI-S (Fig. 1) and HIV serostatus (Fig. 1), among others. We
did this to explore whether the trends fell in the direction of
the oral naltrexone legacy hypothesis (greater naltrexone ef-
fect among patients with lower severity at baseline), but the
trends for XR-NTX were, if anything, independent of base-
line patient severity, that is, with XR-NTX, patients with high
baseline severity had a rate of good clinical outcome that was
similar to those with low baseline severity. Again, it must be
emphasized the interactions were not significant, and these
descriptive data are of mainly heuristic interest for planning
future research.
The study has limitations, first of which is the post
hoc predictors design. The study was not powered to detect
subgroup differences. Future studies attempting to delineate
patient-treatment matching factors should probably plan for
larger sample sizes. The large number of analyses creates the
opportunity for inflated type I error. Another limitation is that
the summary outcome variable examined in this analysis (per-
centage of patients who achieved ≥90% confirmed abstinent
weeks) assumes that dropouts are not abstinent. This is an
imputation, but it seems reasonable, given that a typical fail-
ure mode in the treatment of opioid dependence is dropout,
concurrent with relapse.
The study was conducted in Russia, and replications
in other nations and cultural settings are needed. Additional
studies have emerged on the effectiveness of XR-NTX across a
broad range of patient populations (Baser et al., 2011; Bigelow
et al., 2012; DeFulio et al., 2012; Crevecoeur-MacPhail et al.,
2014); these and future studies should examine the interactions
between patient characteristics and outcome. One important
feature of the Russian clinical settings is the availability of long
hospital stays for detoxification and stabilization. The patients
in this trial were detoxified without use of opioid agonists and
were in the hospital for an average of 18 (standard deviation
= 8) days before starting XR-NTX. This differs from typical
treatment settings in the United States, for example, where
hospitalizations for opioid detoxification typically last for 1
week or less, and opioid tapers with methadone or buprenor-
phine are typically used to minimize withdrawal symptoms.
Level of opioid use before hospital admission, operationalized
as self-reported bags of heroin per day, has been shown
in such US settings to be associated with lower treatment
retention on oral naltrexone (Sullivan et al., 2006; Sullivan
et al., 2007; Carpenter et al., 2009). This is likely because
starting naltrexone soon after stopping opioids may involve
some degree of precipitated withdrawal. Thus, the relatively
long duration between last opioid use and XR-NTX induction
in this study might explain the lack of adverse prognostic
effect of severity on XR-NTX treatment outcome. Again,
future studies are needed to examine the relationship between
severity and outcome of XR-NTX treatment in clinical settings
where detoxification stays are shorter and utilize agonist
tapers.
CONCLUSIONS
We hypothesized, based on the aforementioned clin-
ical experience and literature on oral naltrexone, that pa-
tient characteristics indicating greater clinical severity would
be associated with less effectiveness of XR-NTX versus
Copyright © 2015 American Society of Addiction Medicine. Unauthorized reproduction of this article is prohibited.
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placebo. However, the analyses show that none of the baseline
variable-by-treatment interactions reached significance. Thus,
there is no evidence of patient-treatment matching factors. The
results suggest that XR-NTXwas effective in promoting absti-
nence from opioids and preventing relapse after detoxification
across 25 different demographic features and clinical severity
characteristics. Therefore, in these patientswho reported an av-
erage of a decade of intravenous heroin dependence, this analy-
sis extends the overall efficacy findings of the multisite, double
blind randomized controlled trial (Krupitsky et al., 2011) with
the additional finding that XR-NTX demonstrated its benefit
versus placebo with patients of both lower and higher severity.
The clinical implications of these findings seem to contradict
conventional wisdom regarding oral naltrexone in opioid de-
pendence. Also, in the absence of empirical predictors, patient
preference may be a reasonable basis for medication selection
with clinicians relying on clinical judgment and then observ-
ing the patient’s clinical response. The findings further suggest
the promise of XR-NTX as an addition to the treatment arma-
mentarium for opioid dependence. More research is needed
in an effort to delineate patient-treatment matching factors for
medication treatments for opioid dependence.
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